Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
CNY 4.52
(5.36%)
CNY 4.52
(5.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -148.98 Million CNY | 9.22% |
| 2022 | -164.11 Million CNY | -330.73% |
| 2021 | 71.12 Million CNY | -60.65% |
| 2020 | 180.74 Million CNY | -18.81% |
| 2019 | 222.62 Million CNY | 6.52% |
| 2018 | 209 Million CNY | 14.88% |
| 2017 | 181.93 Million CNY | 39.29% |
| 2016 | 130.61 Million CNY | -24.22% |
| 2015 | 172.35 Million CNY | 5.16% |
| 2014 | 163.9 Million CNY | 26.08% |
| 2013 | 129.99 Million CNY | 4.66% |
| 2012 | 124.21 Million CNY | 89.92% |
| 2011 | 65.39 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -28.93 Million CNY | -65.8% |
| 2024 Q1 | -17.44 Million CNY | 68.27% |
| 2024 Q3 | -27.68 Million CNY | 4.32% |
| 2023 Q1 | -20.99 Million CNY | 82.64% |
| 2023 FY | -148.98 Million CNY | 9.22% |
| 2023 Q4 | -54.98 Million CNY | -109.65% |
| 2023 Q3 | -26.22 Million CNY | 43.91% |
| 2023 Q2 | -46.76 Million CNY | -122.69% |
| 2022 Q4 | -120.97 Million CNY | -9.14% |
| 2022 Q3 | -110.84 Million CNY | -775.75% |
| 2022 Q2 | 16.4 Million CNY | -31.95% |
| 2022 Q1 | 24.1 Million CNY | 217.65% |
| 2022 FY | -164.11 Million CNY | -330.73% |
| 2021 Q1 | 43.14 Million CNY | 341.72% |
| 2021 Q4 | -20.48 Million CNY | -236.9% |
| 2021 Q3 | 14.96 Million CNY | -55.33% |
| 2021 Q2 | 33.5 Million CNY | -22.34% |
| 2021 FY | 71.12 Million CNY | -60.65% |
| 2020 Q3 | 84.44 Million CNY | 559.85% |
| 2020 FY | 180.74 Million CNY | -18.81% |
| 2020 Q2 | 12.79 Million CNY | -82.64% |
| 2020 Q1 | 73.73 Million CNY | 35.41% |
| 2020 Q4 | 9.76 Million CNY | -88.43% |
| 2019 Q4 | 54.45 Million CNY | 16.14% |
| 2019 Q2 | 82.07 Million CNY | 109.35% |
| 2019 Q1 | 39.2 Million CNY | -52.66% |
| 2019 Q3 | 46.88 Million CNY | -42.88% |
| 2019 FY | 222.62 Million CNY | 6.52% |
| 2018 Q4 | 82.82 Million CNY | 85.45% |
| 2018 FY | 209 Million CNY | 14.88% |
| 2018 Q3 | 44.66 Million CNY | -1.46% |
| 2018 Q2 | 45.32 Million CNY | 25.2% |
| 2018 Q1 | 36.19 Million CNY | -54.3% |
| 2017 Q1 | 31.56 Million CNY | -12.95% |
| 2017 Q2 | 35.35 Million CNY | 12.0% |
| 2017 Q3 | 35.78 Million CNY | 1.22% |
| 2017 Q4 | 79.22 Million CNY | 121.36% |
| 2017 FY | 181.93 Million CNY | 39.29% |
| 2016 Q1 | 32.57 Million CNY | -44.29% |
| 2016 FY | 130.61 Million CNY | -24.22% |
| 2016 Q2 | 30.13 Million CNY | -7.51% |
| 2016 Q3 | 31.63 Million CNY | 4.99% |
| 2016 Q4 | 36.26 Million CNY | 14.64% |
| 2015 Q4 | 58.48 Million CNY | 68.83% |
| 2015 Q3 | 34.63 Million CNY | -28.1% |
| 2015 Q2 | 48.17 Million CNY | 55.14% |
| 2015 Q1 | 31.05 Million CNY | -48.58% |
| 2015 FY | 172.35 Million CNY | 5.16% |
| 2014 Q2 | 44.2 Million CNY | 40.22% |
| 2014 FY | 163.9 Million CNY | 26.08% |
| 2014 Q4 | 60.39 Million CNY | 117.47% |
| 2014 Q1 | 31.52 Million CNY | 0.0% |
| 2014 Q3 | 27.77 Million CNY | -37.17% |
| 2013 FY | 129.99 Million CNY | 4.66% |
| 2012 FY | 124.21 Million CNY | 89.92% |
| 2011 FY | 65.39 Million CNY | 0.0% |